Axsome is close to a $500m revenue per annum company with potential to achieve >$1bn per annum by 2030. Read the full AXSM stock analysis here.

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Mixed analysts’ ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...